Neon Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Neon Therapeutics's estimated annual revenue is currently $14.1M per year.
- Neon Therapeutics received $36.0M in venture funding in December 2017.
- Neon Therapeutics's estimated revenue per employee is $111,063
- Neon Therapeutics's total funding is $261M.
- Neon Therapeutics has 127 Employees.
- Neon Therapeutics grew their employee count by 0% last year.
- Neon Therapeutics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Cell Signaling ...||$89.4M||577||N/A||N/A|
What Is Neon Therapeutics?
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. For more information, please visit www.neontherapeutics.com.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Marc Wolfgang||VP, Technical Operations||Email Available|
|Richard Gaynor||President, Research And Development|
|Zach Taylor||Senior Director, Business Development and Strategy|
|Seth Harmon||Senior Director Of Finance And Accounting||Email Available|
|Kerry Chios||Associate Director||Email Available|
|Todd Kenney||Head Of Quality, Senior Director Quality Assurance||Email Available|
|Kathryn Landes||Director Gmp Qa||Email Available|
|John Curran||Director, Sequencing Operations||Email Available|
|Karyn Hoffman||Executive Assistant To The Chief Executive Officer||Email Available|
|Yasir Al-Wakeel||CFO||Email Available|
Neon Therapeutics News
Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens.
Thinly traded nano cap Neon Therapeutics (NASDAQ:NTGN) is up 14% premarket on average volume in response to a just-published paper in ...
Neon Therapeutics Inc (NTGN) stock has fallen -66.87% over the last 12 months, and the average rating from Wall Street analysts is a Strong ...
Neon Therapeutics Funding
|2015-10-02||$55.0M||A||Third Rock Ventures||Article|
|2017-01-06||$70.0M||B||Partner Fund Management||Article|
Neon Therapeutics Executive Hires
|2016-11-08||Richard Gaynor||Pres Research & Development||Article|
|2017-06-19||Yasir Al-Wakeel||Chief Financial Officer||Article|
|2017-08-16||Teresa Regan||VP Human Resources||Article|